Does the media prefer BTSG or CAI?

In the previous week, BrightSpring Health Services had 18 more articles in the media than Caris Life Sciences. MarketBeat recorded 22 mentions for BrightSpring Health Services and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat BrightSpring Health Services' score of 0.91 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BrightSpring Health Services 9 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer CAI or FMS?

In the previous week, Caris Life Sciences and Caris Life Sciences both had 4 articles in the media. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.78 beat Caris Life Sciences' score of 1.76 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Fresenius Medical Care AG & Co. KGaA 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to PACS or CAI?

In the previous week, PACS Group had 4 more articles in the media than Caris Life Sciences. MarketBeat recorded 8 mentions for PACS Group and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat PACS Group's score of 1.16 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Caris Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to HIMS or CAI?

In the previous week, Hims & Hers Health had 21 more articles in the media than Caris Life Sciences. MarketBeat recorded 25 mentions for Hims & Hers Health and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat Hims & Hers Health's score of 0.22 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hims & Hers Health 5 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 2 Very Negative mention(s) Neutral Caris Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to BLLN or CAI?

In the previous week, Billiontoone had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for Billiontoone and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat Billiontoone's score of 0.41 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Caris Life Sciences (CAI) Competitors

$15.67 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$15.55 -0.12 (-0.77%)

As of 07/31/2026 07:34 PM Eastern

Compare

CAI vs. BTSG, FMS, PACS, HIMS, and BLLN

Should you buy Caris Life Sciences stock or one of its competitors? MarketBeat compares Caris Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caris Life Sciences include BrightSpring Health Services (BTSG), Fresenius Medical Care AG & Co. KGaA (FMS), PACS Group (PACS), Hims & Hers Health (HIMS), and Billiontoone (BLLN).

How does Caris Life Sciences compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.

BrightSpring Health Services has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than BrightSpring Health Services, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	0.91	$190.67M	$1.41	42.35
Caris Life Sciences	$812.03M	5.45	-$68.09M	-$7.61	N/A

Caris Life Sciences has a net margin of 3.75% compared to BrightSpring Health Services' net margin of 2.55%. Caris Life Sciences' return on equity of 98.28% beat BrightSpring Health Services' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.55%	16.73%	5.24%
Caris Life Sciences	3.75%	98.28%	48.87%

In the previous week, BrightSpring Health Services had 18 more articles in the media than Caris Life Sciences. MarketBeat recorded 22 mentions for BrightSpring Health Services and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat BrightSpring Health Services' score of 0.91 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	9 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BrightSpring Health Services currently has a consensus target price of $70.12, suggesting a potential upside of 17.43%. Caris Life Sciences has a consensus target price of $26.11, suggesting a potential upside of 66.63%. Given Caris Life Sciences' higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

BrightSpring Health Services has a beta of 1.88, suggesting that its stock price is 88% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

BrightSpring Health Services beats Caris Life Sciences on 9 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Caris Life Sciences (NASDAQ:CAI) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

8.4% of Fresenius Medical Care AG & Co. KGaA shares are owned by institutional investors. 50.0% of Caris Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Caris Life Sciences presently has a consensus price target of $26.11, suggesting a potential upside of 66.63%. Fresenius Medical Care AG & Co. KGaA has a consensus price target of $23.95, suggesting a potential downside of 6.68%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Caris Life Sciences is more favorable than Fresenius Medical Care AG & Co. KGaA.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.55

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Fresenius Medical Care AG & Co. KGaA, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.45	-$68.09M	-$7.61	N/A
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.62	$1.11B	$1.90	13.51

Caris Life Sciences has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Fresenius Medical Care AG & Co. KGaA has a net margin of 4.88% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%

In the previous week, Caris Life Sciences and Caris Life Sciences both had 4 articles in the media. Fresenius Medical Care AG & Co. KGaA's average media sentiment score of 1.78 beat Caris Life Sciences' score of 1.76 indicating that Fresenius Medical Care AG & Co. KGaA is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Fresenius Medical Care AG & Co. KGaA	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Fresenius Medical Care AG & Co. KGaA beats Caris Life Sciences on 8 of the 15 factors compared between the two stocks.

How does Caris Life Sciences compare to PACS Group?

PACS Group (NYSE:PACS) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

PACS Group has a beta of -0.08, suggesting that its stock price is 108% less volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

PACS Group presently has a consensus price target of $50.60, indicating a potential upside of 9.72%. Caris Life Sciences has a consensus price target of $26.11, indicating a potential upside of 66.63%. Given Caris Life Sciences' higher probable upside, analysts clearly believe Caris Life Sciences is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

PACS Group has a net margin of 4.49% compared to Caris Life Sciences' net margin of 3.75%. Caris Life Sciences' return on equity of 98.28% beat PACS Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PACS Group	4.49%	26.47%	4.36%
Caris Life Sciences	3.75%	98.28%	48.87%

In the previous week, PACS Group had 4 more articles in the media than Caris Life Sciences. MarketBeat recorded 8 mentions for PACS Group and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat PACS Group's score of 1.16 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PACS Group	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Caris Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

PACS Group has higher revenue and earnings than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PACS Group	$5.43B	1.34	$191.54M	$1.56	29.56
Caris Life Sciences	$812.03M	5.45	-$68.09M	-$7.61	N/A

Summary

PACS Group and Caris Life Sciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Caris Life Sciences compare to Hims & Hers Health?

Hims & Hers Health (NYSE:HIMS) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Hims & Hers Health has a beta of 2.4, meaning that its share price is 140% more volatile than the broader market. Comparatively, Caris Life Sciences has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market.

Caris Life Sciences has a net margin of 3.75% compared to Hims & Hers Health's net margin of -0.56%. Caris Life Sciences' return on equity of 98.28% beat Hims & Hers Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hims & Hers Health	-0.56%	6.10%	1.52%
Caris Life Sciences	3.75%	98.28%	48.87%

In the previous week, Hims & Hers Health had 21 more articles in the media than Caris Life Sciences. MarketBeat recorded 25 mentions for Hims & Hers Health and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat Hims & Hers Health's score of 0.22 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hims & Hers Health	5 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	6 Negative mention(s)	2 Very Negative mention(s)	Neutral
Caris Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Hims & Hers Health currently has a consensus price target of $31.43, suggesting a potential upside of 13.12%. Caris Life Sciences has a consensus price target of $26.11, suggesting a potential upside of 66.63%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Caris Life Sciences is more favorable than Hims & Hers Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hims & Hers Health	1 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.19
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

63.5% of Hims & Hers Health shares are held by institutional investors. 11.8% of Hims & Hers Health shares are held by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hims & Hers Health has higher revenue and earnings than Caris Life Sciences. Hims & Hers Health is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hims & Hers Health	$2.35B	2.74	$128.37M	-$0.09	N/A
Caris Life Sciences	$812.03M	5.45	-$68.09M	-$7.61	N/A

Summary

Caris Life Sciences beats Hims & Hers Health on 10 of the 16 factors compared between the two stocks.

How does Caris Life Sciences compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Caris Life Sciences (NASDAQ:CAI) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

Billiontoone currently has a consensus target price of $126.00, suggesting a potential downside of 9.09%. Caris Life Sciences has a consensus target price of $26.11, suggesting a potential upside of 66.63%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

In the previous week, Billiontoone had 1 more articles in the media than Caris Life Sciences. MarketBeat recorded 5 mentions for Billiontoone and 4 mentions for Caris Life Sciences. Caris Life Sciences' average media sentiment score of 1.76 beat Billiontoone's score of 0.41 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Caris Life Sciences has a net margin of 3.75% compared to Billiontoone's net margin of 0.00%. Caris Life Sciences' return on equity of 98.28% beat Billiontoone's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
Caris Life Sciences	3.75%	98.28%	48.87%

Billiontoone has higher earnings, but lower revenue than Caris Life Sciences. Caris Life Sciences is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$305.11M	20.89	$7.45M	$0.55	252.00
Caris Life Sciences	$812.03M	5.45	-$68.09M	-$7.61	N/A

Summary

Billiontoone and Caris Life Sciences tied by winning 6 of the 12 factors compared between the two stocks.

Get Caris Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CAI vs. The Competition

Export

Metric	Caris Life Sciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.43B	$9.08B	$6.86B	$12.42B
Dividend Yield	N/A	1.47%	2.59%	10.03%
P/E Ratio	-2.06	58.59	282.27	24.66
Price / Sales	5.45	102.94	563.88	76.67
Price / Cash	9.83	25.63	28.60	46.71
Price / Book	7.64	5.04	10.93	6.07
Net Income	-$68.09M	$57.47B	$3.49B	$347.99M
7 Day Performance	0.26%	-0.08%	-0.61%	-0.42%
1 Month Performance	-14.37%	-4.38%	-3.75%	-4.80%
1 Year Performance	N/A	14.98%	62.10%	18.61%

Caris Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CAI Caris Life Sciences	4.8222 of 5 stars	$15.67 flat	$26.11 +66.6%	N/A	$4.43B	$812.03M	N/A	1,846	Positive News Gap Up
BTSG BrightSpring Health Services	4.904 of 5 stars	$72.91 +4.4%	$70.12 -3.8%	+204.0%	$14.38B	$12.91B	51.71	23,500	Trending News Earnings Report Gap Up
FMS Fresenius Medical Care AG & Co. KGaA	3.8143 of 5 stars	$24.58 +0.6%	$28.00 +13.9%	+2.2%	$13.21B	$22.20B	12.93	1,488	Positive News Upcoming Earnings
PACS PACS Group	3.5244 of 5 stars	$46.73 +4.3%	$50.60 +8.3%	+334.3%	$7.42B	$5.29B	29.96	47,455	Upcoming Earnings
HIMS Hims & Hers Health	3.1428 of 5 stars	$28.10 -14.2%	$31.43 +11.9%	-55.6%	$6.50B	$2.35B	N/A	2,442	Trending News Upcoming Earnings Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CAI) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caris Life Sciences (CAI) Competitors

CAI vs. BTSG, FMS, PACS, HIMS, and BLLN

How does Caris Life Sciences compare to BrightSpring Health Services?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Caris Life Sciences compare to PACS Group?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Summary

How does Caris Life Sciences compare to Billiontoone?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caris Life Sciences (CAI) Competitors

CAI vs. BTSG, FMS, PACS, HIMS, and BLLN

How does Caris Life Sciences compare to BrightSpring Health Services?

Which has better valuation & earnings, BTSG or CAI?

Is BTSG or CAI more profitable?

Does the media prefer BTSG or CAI?

Do analysts recommend BTSG or CAI?

Which has more volatility and risk, BTSG or CAI?

Summary

How does Caris Life Sciences compare to Fresenius Medical Care AG & Co. KGaA?

Do insiders and institutionals hold more shares of CAI or FMS?

Do analysts recommend CAI or FMS?

Which has better earnings & valuation, CAI or FMS?

Which has more risk & volatility, CAI or FMS?

Is CAI or FMS more profitable?

Does the media prefer CAI or FMS?

Summary

How does Caris Life Sciences compare to PACS Group?

Which has more risk & volatility, PACS or CAI?

Do analysts prefer PACS or CAI?

Is PACS or CAI more profitable?

Does the media refer more to PACS or CAI?

Which has better valuation and earnings, PACS or CAI?

Summary

How does Caris Life Sciences compare to Hims & Hers Health?

Which has more volatility and risk, HIMS or CAI?

Is HIMS or CAI more profitable?

Does the media refer more to HIMS or CAI?

Do analysts recommend HIMS or CAI?

Do insiders & institutionals hold more shares of HIMS or CAI?

Which has higher valuation and earnings, HIMS or CAI?

Summary

How does Caris Life Sciences compare to Billiontoone?

Do analysts recommend BLLN or CAI?

Does the media refer more to BLLN or CAI?

Is BLLN or CAI more profitable?

Which has better earnings and valuation, BLLN or CAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CAI vs. The Competition

Caris Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools